|
| Human LRG1 Protein (LTP10493) |
|
| LTP10493 |
|
| 100ug |
|
|
$450 In stock |
| Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN. |
| Recombinant Human LRG1 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Val36-Gln347. |
|
| LRG1 |
|
| Human |
|
| P02750 |
|
| Val36-Gln347 |
|
| The protein has a predicted MW of 35.4 kDa. Due to glycosylation, the protein migrates to 48-52 kDa based on the Tris-Bis PAGE result. |
|
| Immobilized Human LRG1, His Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-LRG1 Antibody, hFc Tag with the EC50 of 8.0ng/ml determined by ELISA. See testing image for detail. |
|
| C-His |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
